Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Expert Opin Investig Drugs. 2011 Oct 6;20(11):1575–1581. doi: 10.1517/13543784.2011.619976

11. DRUG SUMMARY BOX

Drug Name: NorLeu3-Angiotensin (1-7)
Phase: Phase II Clinical Trial
Indication: Acceleration of closure of diabetic foot ulcer
Pharmacological Description/Mechanism of Action: The mechanisms of action include induction of progenitor proliferation and accelerated vascularization, collagen deposition and re-epithelialization.
Route of administration: Topical
Chemical Structure: H2N-Asp-Arg-NorLeu-Tyr-Ile-His-Pro-OH
Pivotal trial(s): To be initiated